Effects of age on a new animal model of tardive dyskinesia

Neurobiology of Aging

Volumn 18, Issue 6, 1997, Pages 623-629

  Bergamo, M ^a   Abilio V C ^a   Queiroz, C M T ^a   Barbosa Junior H N ^a   Abdanur, L R A ^a   Frussa Filho, R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Oral dyskinesia; Rats; Reserpine; Senility

Indexed keywords

NEUROLEPTIC AGENT; RESERPINE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FACE MUSCLE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SENILITY; SUPERSENSITIVITY; TARDIVE DYSKINESIA;

AGING; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; MALE; MOUTH; RATS; RATS, WISTAR; RESERPINE;

EID: 0344863118     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(97)00152-8     Document Type: Article

References (51)

1. Baldessarini R. J., Tarsy D. Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Int. Rev. Neurobiol. 21:1979;1-45.
2. Benzi G., Moretti A. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radical Biol. Med. 19:1995;77-101.
3. Bernardi M. M., De Souza H., Palermo-Neto J. Effects of single and long-term haloperidol administration on open-field behavior of rats. Psychopharmacol. 73:1981;171-175.
4. Burt D. R., Creese I., Snyder S. H. Antischizophrenic drugs Chronic treatment elevates dopaminergic receptor in brain . Science. 196:1977;326-327.
5. Casey D. E. Tardive dyskinesia - Pathophysiology. Bloom F. E., Kupfer D. J. Psychopharmacology The Fourth generation of Progress . 1995;1497-1502 Raven Press Ltd. New York.
6. Casey D. E. Tardive dyskinesia reversible and irreversible. Casey D. E., Chase T. N., Christensen A. V., Gerlach J. Dyskinesia Research and Treatment . 1985;88-98 Springer-Verlag, Berlim.
7. Clemens J. A., Panetta A. Free-radicals in central nervous system diseases. Winyard P. G. Immunopharmacology of Free-Radical Species. 1995;73-83 Academic Press Limited, London.
8. Egan M. F., Hyde T. M., Albers G. W., Elkashef A., Alexander R. C., Reeve A., Blum A., Saenz R. E., Wyatt R. J. Treatment of tardive dyskinesia with vitamin E. Am. J. Psychiatry. 149:1992;773-777.
9. Elkashef A. M., Ruskin P. E., Bacher N., Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am. J. Psychiatry. 147:1990;505-506.
10. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term of metoclopramide administration on open-field and stereotyped behavior of rats. Eur. J. Pharmacol. 149:1988;323-329.
11. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term of sulpiride administration on open-field and stereotyped behavior of rats. Braz. J. Med. Biol. Res. 23:1990;463-472.
12. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term droperidol administration on open-field and stereotyped behavior of rats. Physiol. Behav. 50:1991;825-830.
13. Gamble S. J., Waddington J. L. Multiplicity of dopamine-mediated behaviours during six months phenothiazine neuroleptic treatment in young but not aged-rats. Br. J. Pharmac. 74:1981;225.
14. Gerlach J. Pathophysiological mechanisms underlying tardive dyskinesia. Casey D. E., Chase T. N., Christensen A. V., Gerlach J. Dyskinesia Research and Treatment . 1985;99-104 Springer-Verlag, Berlim.
15. 3H-SCH 23390 decrease in the striatum of aged rats . Neurobiol. Aging. 8:1987;51-54.
16. 1 - dopamine receptors and dopamine content in the rat striatum. Develop. Brain Res. 35:1987;283-290.
17. 3H-spiroperidol binding in rat striatum during aging. J. Pharm. Pharmacol. 30:1978;448-449.
18. Gunne L. M., Haggstrom J. E. Reduction in nigral glutamic acid descarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology. 81:1983;191-194.
19. Gunne L. M., Andersson U., Bondesson U., Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol. Biochem. Behav. 25:1986;897-901.
20. Johansson P., Casey D. E., Gunne L. M. Dose-dependent increases in rat spontaneous chewing in rates during long-term administration of haloperidol but not clozapine. Psychopharmacol. Bull. 22:1986;1017-1019.
21. Johnson N., Leone F. Statistic and experimental design. Johnson N., Leone F. Engineering and Physical Sciences. 1974;34-45 John Wiley & Sons, New York.
22. Joseph J. A., Berger R. E., Engle B. T., Roth G. S. Age-related changes in the neostriatum A behavioral and biochemical analysis . J. Gerontol. 33:1978;643-649.
23. Kane J. M., Woerner M., Lieberman J. Tardive dyskinesia Prevalence, incidence and risk factors . Casey D. E., Chase T. N., Christensen A. V., Gerlach J. Dyskinesia Research and Treatment . 1985;72-78 Springer-Verlag, Berlim.
24. Klawans H. L. The pharmacology of tardive dyskinesia. Am. J. Psychiat. 130:1973;82-86.
25. Lohr J. B. Oxygen free radicals and neuropsychiatric illness. Arch. Gen. Psychiatry. 48:1991;1097-1106.
26. Lohr J. B., Cadet J. L., Lohr M. A., Jeste D. V., Wyatt R. J. Alpha-tocopherol in tardive dyskinesia. Lancet. 1:1987;913-914.
27. Mak T., Boehme P., Weglicki W. B. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Circulation Res. 70:1992;1099-1103.
28. 2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol. Biochem. Behav. 45:1993;195-200.
29. Marsden C. D. Is tardive dyskinesia a unique disorder? Casey D. E., Chase T. N., Christensen A. V., Gerlach J. Dyskinesia Research and Treatment . 1985;67-71 Springer-Verlag, Berlim.
30. Maulik N., Das D. K., Gogineni M., Cordis G. A., Avrova N., Denisova N. Reduction of myocardial ischemic reperfusion injury by sialylated glycosphingolipids, gangliosides. J. Cardiovasc. Pharmacol. 22:1993;74-81.
31. Misra C. H., Shelat H., Smith R. C. Age affects dopamine receptors changes during chronic administration of fluphenazine. Eur. J. Pharmacol. 85:1982;343-346.
32. Mithani S., Atmadja S., Baimbridge K. G., Fibiger H. C. Neuroleptic-induced oral dyskinesias effects of progabide and lack of correlation with regional changes in glutamic acid descarboxylase and choline acetyltransferase activities . Psychopharmacology. 93:1987;94-100.
33. Morgan D. The dopamine and serotonin systems during aging in human and rodent brain. A brief review. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 11:1987;153-157.
34. Neisewander J. L., Castañeda E., Davis D. A. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats Support for a model of tardive dyskinesia . Psychopharmacology. 116:1994;79-84.
35. Neisewander J. L., Lucki I., Mcgonigle P. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257:1991;850-860.
36. Neisewander J. L., Lucki I., Mcgonigle P. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res. 558:1991;27-35.
37. Randall P. K., Severson J. A., Finch C. E. Aging and the regulation of striatal dopaminergic mechanisms in mice. J. Pharmacol. Exp. Ther. 219:1981;695-700.
38. Roth G. S., Joseph J. A. Age-related changes in transcriptional and posttranscriptional regulation of the dopaminergic system. Life Sci. 55:1994;2031-2035.
39. Rupniak N. M. J., Mann S., Hall M. D., Fleminger S., Kilpatrick G., Jenner P., Marsden C. D. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. Psychopharmacology. 84:1984;503-511.
40. Seeman P. Brain dopamine receptors. Pharmacology Rev. 32:1980;229-313.
41. Severson J. A., Finch C. E. Reduced dopaminergic binding during aging in the rodent striatum. Brain Res. 192:1980;147-162.
42. Shonecker M. Ein eigentumliches syndrom in eralen Bereich bei. Megaphen Applikation Nervenartz. 28:1957;34.
43. Shriqui C. L., Bradwejn J., Annable L., Jones B. D. Vitamin E in the treatment of tardive dyskinesia A double-blind placebo-controlled study . Am. J. Psychiatry. 149:1992;391-393.
44. Siegel, S. Nonparametric statistic for the behavioral sciences. McGraw-Hill, New York; 1956:117-127.
45. Uhrbrand L., Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia. 1:1960;408-418.
46. 1 on dopaminergic supersensitivity. Life Sci. 56:(26):1995;2299-2307.
47. Waddington J. L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration phenomenology, pathophysiology and putative relationship to tardive dyskinesia . Psychopharmacology. 101:1990;431-447.
48. Waddington J. L., Gamble S. J. Differential effects of ageing on distincts features of apomorphine stereotypy in the adult rat. Neurosci. Lett. 20:1980;95-99.
49. Waddington J. L., Molloy A. G., O'Boyle K. M. Behavioural effects of long-term treatment with further typical neuroleptics and seletive D-2 dopamine receptor antagonists in young vs aged animals. Sandler M., Dahlstrom A., Belmaker R. Progress in Catecholamine Research Part B: Central Aspects . 1988;43-46 Liss, New York.
50. Waddington J. L., Youssef H. A., Molloy A. G., O'Boyle K. M., Pugh M. T. Association of intellectual impairment, negative symptoms and aging with abnormal, involuntary movements ("tardive" dyskinesia) in schizophrenia Clinical and animal studies . J. Clin. Psychiatry. 46:1985;29-33.
51. Wolfarth S., Ossowska K. Can supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog. Neuro-Psychopharmacol. Biol. Psychiat. 13:1989;789-840.